Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy.
Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
Interv Cardiol Clin. 2024 Oct;13(4):527-541. doi: 10.1016/j.iccl.2024.07.001. Epub 2024 Aug 3.
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is fundamental in all patients undergoing percutaneous coronary intervention (PCI) to prevent coronary thrombosis. In patients with atrial fibrillation (AF), an oral anticoagulant gives protection against ischemic stroke or systemic embolism. AF-PCI patients are at high bleeding risk and decision-making regarding the optimal antithrombotic therapy remains challenging. Dual antithrombotic therapy (DAT) has been shown to reduce bleeding events but at the cost of a higher risk of stent thrombosis. Further studies are needed to clarify the optimal duration of triple antithrombotic therapy (TAT) or DAT and the role of more potent antiplatelet drugs.
双联抗血小板治疗（阿司匹林和 P2Y12 抑制剂）是所有行经皮冠状动脉介入治疗（PCI）患者的基础治疗，以预防冠状动脉血栓形成。在患有心房颤动（AF）的患者中，口服抗凝剂可预防缺血性卒中和全身性栓塞。AF-PCI 患者出血风险较高，最佳抗血栓治疗决策仍然具有挑战性。双联抗栓治疗（DAT）已被证明可降低出血事件的发生，但代价是支架血栓形成的风险增加。需要进一步的研究来阐明三联抗栓治疗（TAT）或 DAT 的最佳持续时间以及更有效的抗血小板药物的作用。
